Meghan C. Thompson, MD
Leukemia Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Chronic Lymphocytic Leukemia (CLL)
- Richter Transformation
- Lymphoproliferative Disorders
About Me
- Assistant Attending Physician
I am a medical oncologist specializing in the care for patients with chronic lymphocytic leukemia (CLL), Richter Transformation, lymphoproliferative disorders, and other leukemias. It is my honor to partner with patients and their families to formulate a personalized care plan based on their cancer biology, medical history, and individual goals. I am passionate about educating patients and their families on their diagnosis and treatment options, as well as learning what is most important to each patient as they begin their care journey with me.
At each visit, I prioritize listening to patients’ concerns and answering their questions. I value teamwork, and at Memorial Sloan Kettering Cancer Center (MSK), I am fortunate to work with a multidisciplinary team of medical oncologists, pathologists, radiologists, radiation oncologists, advanced practice providers, nurses, pharmacists, and social workers to provide outstanding, cutting-edge cancer care.
Read more
I conduct clinical research with the goal of improving treatment outcomes and the quality of life for patients with CLL and Richter Transformation. Together with colleagues in the CLL program at MSK, I help design and lead clinical trials that investigate new interventions for patients with CLL and Richter Transformation. I also partner with laboratory scientists at MSK to understand how different therapeutic strategies impact CLL genetics, including why certain treatments do or do not work for patients in specific situations. I am proud to be part of a team of expert cancer clinicians and scientists working to provide the highest quality care to patients and ultimately, improve the lives of people with blood cancers.
A leukemia specialist is a doctor with special training in diagnosing and treating leukemia.
My Specialties
- Chronic Lymphocytic Leukemia (CLL)
- Richter Transformation
- Lymphoproliferative Disorders
Education
- MD, The Ohio State University College of Medicine
Residencies
- Internal Medicine - Hospital of the University of Pennsylvania
Awards and Honors
- Abstract Achievement Award, American Society of Hematology (2020, 2021)
- Alpha Omega Alpha Society, 2015
Fellowships
- Hematology & Medical Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Hematology
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. Thompson sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Thompson
- A Phase 1 Study of ABBV-525 in People With B-Cell Lymphoma
- A Phase I Study of BGB-16673 in People with B Cell Cancers
- A Phase I Study of Epcoritamab in People with Relapsed or Persistent Chronic Lymphocytic Leukemia
- A Study Assessing Minimal Residual Disease to Minimize Side Effects in People with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Treated with Venetoclax
Read more
- Clinical Trials Co-Investigated by Dr. Thompson
- A Phase 1 Study of DZD8586 in People With B-Cell Non-Hodgkin Lymphoma
- A Phase 1 Study of NX-5948 in People With B-Cell Lymphoma/Leukemia
- A Phase 2 Study of Venetoclax, Obinutuzumab, and Acalabrutinib to Treat Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- A Phase III Study Assessing Early versus Delayed Treatment with Venetoclax and Obinutuzumab for Newly Diagnosed Patients with High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma without Symptoms
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Thompson’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Meghan C. Thompson discloses the following relationships and financial interests:
-
AbbVie
Professional Services and Activities -
AstraZeneca
Professional Services and Activities -
BeiGene USA, Inc.
Professional Services and Activities -
Dava Oncology
Professional Services and Activities -
Janssen Global Services, LLC
Professional Services and Activities
-
Janssen Scientific Affairs, LLC
Professional Services and Activities -
Loxo Oncology
Professional Services and Activities -
PeerView Institute for Medical Education (PVI)
Professional Services and Activities -
Phillips Group Oncology Communications, Inc.
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].